Advances in Immunosuppressive Agents Based on Signal Pathway
Immune abnormality involves in various diseases, such as infection, allergic diseases, autoimmune diseases, as well as transplantation. Several signal pathways have been demonstrated to play a central role in the immune response, including JAK/STAT, NF-κB, PI3K/AKT-mTOR, MAPK, and Keap1/Nrf2/ARE pat...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.917162/full |
| _version_ | 1811256242032607232 |
|---|---|
| author | Zhiqing Xu Zhiqing Xu Ming Chu |
| author_facet | Zhiqing Xu Zhiqing Xu Ming Chu |
| author_sort | Zhiqing Xu |
| collection | DOAJ |
| description | Immune abnormality involves in various diseases, such as infection, allergic diseases, autoimmune diseases, as well as transplantation. Several signal pathways have been demonstrated to play a central role in the immune response, including JAK/STAT, NF-κB, PI3K/AKT-mTOR, MAPK, and Keap1/Nrf2/ARE pathway, in which multiple targets have been used to develop immunosuppressive agents. In recent years, varieties of immunosuppressive agents have been approved for clinical use, such as the JAK inhibitor tofacitinib and the mTOR inhibitor everolimus, which have shown good therapeutic effects. Additionally, many immunosuppressive agents are still in clinical trials or preclinical studies. In this review, we classified the immunosuppressive agents according to the immunopharmacological mechanisms, and summarized the phase of immunosuppressive agents. |
| first_indexed | 2024-04-12T17:37:10Z |
| format | Article |
| id | doaj.art-e8554e96ec9e49d0a8c71df97242f571 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T17:37:10Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-e8554e96ec9e49d0a8c71df97242f5712022-12-22T03:22:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-05-011310.3389/fphar.2022.917162917162Advances in Immunosuppressive Agents Based on Signal PathwayZhiqing Xu0Zhiqing Xu1Ming Chu2Department of Immunology, National Health Commission (NHC) Key Laboratory of Medical Immunology (Peking University), School of Basic Medical Sciences, Peking University, Beijing, ChinaDepartment of Pharmacology, Jilin University, Changchun, ChinaDepartment of Immunology, National Health Commission (NHC) Key Laboratory of Medical Immunology (Peking University), School of Basic Medical Sciences, Peking University, Beijing, ChinaImmune abnormality involves in various diseases, such as infection, allergic diseases, autoimmune diseases, as well as transplantation. Several signal pathways have been demonstrated to play a central role in the immune response, including JAK/STAT, NF-κB, PI3K/AKT-mTOR, MAPK, and Keap1/Nrf2/ARE pathway, in which multiple targets have been used to develop immunosuppressive agents. In recent years, varieties of immunosuppressive agents have been approved for clinical use, such as the JAK inhibitor tofacitinib and the mTOR inhibitor everolimus, which have shown good therapeutic effects. Additionally, many immunosuppressive agents are still in clinical trials or preclinical studies. In this review, we classified the immunosuppressive agents according to the immunopharmacological mechanisms, and summarized the phase of immunosuppressive agents.https://www.frontiersin.org/articles/10.3389/fphar.2022.917162/fullimmunosuppressive agentjak-statNF-κBPI3K-AKT-mTORMAPKKeap1/Nrf2-ARE |
| spellingShingle | Zhiqing Xu Zhiqing Xu Ming Chu Advances in Immunosuppressive Agents Based on Signal Pathway Frontiers in Pharmacology immunosuppressive agent jak-stat NF-κB PI3K-AKT-mTOR MAPK Keap1/Nrf2-ARE |
| title | Advances in Immunosuppressive Agents Based on Signal Pathway |
| title_full | Advances in Immunosuppressive Agents Based on Signal Pathway |
| title_fullStr | Advances in Immunosuppressive Agents Based on Signal Pathway |
| title_full_unstemmed | Advances in Immunosuppressive Agents Based on Signal Pathway |
| title_short | Advances in Immunosuppressive Agents Based on Signal Pathway |
| title_sort | advances in immunosuppressive agents based on signal pathway |
| topic | immunosuppressive agent jak-stat NF-κB PI3K-AKT-mTOR MAPK Keap1/Nrf2-ARE |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.917162/full |
| work_keys_str_mv | AT zhiqingxu advancesinimmunosuppressiveagentsbasedonsignalpathway AT zhiqingxu advancesinimmunosuppressiveagentsbasedonsignalpathway AT mingchu advancesinimmunosuppressiveagentsbasedonsignalpathway |